Payment overview · 2025
General Payments
$1,192.65
58 reported records · 13 companies
Healthcare provider profile · identity verified
Raj Patel
Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease · IRVINGTON, NJ · NPI 1457710980
Verified facts
What the public records show
CMS Open Payments records show Raj Patel received $1,192.65 in general payments during 2025 across 58 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Cabenuva, Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Descovy by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DELSTRIGO as an associated drug or biological on 864 records involving 608 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Delstrigo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Dovato by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RUKOBIA as an associated drug or biological on 3367 records involving 1303 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rukobia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $249.82 | 20.9% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $240.75 | 20.2% | 11 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $218.84 | 18.4% | 16 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $138.59 | 11.6% | 9 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $130.93 | 11.0% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $60.08 | 5.0% | 3 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $33.70 | 2.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.20 | 2.8% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.00 | 1.9% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $16.71 | 1.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.51 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.46 | 1.3% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.06 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,192.65 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $204.14 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $200.51 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $176.15 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $138.59 | 9 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $60.08 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.61 | 4 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.20 | 2 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $26.18 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| Veklury Normalized: veklury |
Drug | Gilead Sciences, Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 68 | exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 17 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | DELSTRIGO open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 608 recipient NPIs · example record 1237993240 |
Delstrigo · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | RUKOBIA open payments reported associated product |
CMS Open Payments — General Payments 3367 supporting records · 1303 recipient NPIs · example record 1189508926 |
Rukobia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 892 | 347 |
| Amlodipine Besylate | Amlodipine Besylate | 597 | 215 |
| Metformin Hcl | Metformin Hcl | 398 | 147 |
| Furosemide | Furosemide | 345 | 146 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 104 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 254 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 250 | 94 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 223 | 84 |
| Carvedilol | Carvedilol | 202 | 75 |
| Losartan Potassium | Losartan Potassium | 199 | 69 |
| Methylprednisolone | Methylprednisolone | 194 | 154 |
| Zolpidem Tartrate | Zolpidem Tartrate | 191 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 57 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 160 | 51 |
| Eliquis | Apixaban | 158 | 44 |
| Azithromycin | Azithromycin | 157 | 135 |
| Potassium Chloride | Potassium Chloride | 148 | 71 |
| Hydralazine Hcl | Hydralazine Hcl | 144 | 56 |
| Gabapentin | Gabapentin | 143 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 140 | 46 |
| Promethazine Hcl | Promethazine Hcl | 131 | 103 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 129 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 46 |
| Naproxen | Naproxen | 127 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 49 |
| Simvastatin | Simvastatin | 116 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 43 |
| Prednisone | Prednisone | 112 | 74 |
| Diclofenac Sodium | Diclofenac Sodium | 100 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 39 |
| Glimepiride | Glimepiride | 94 | 38 |
| Lisinopril | Lisinopril | 94 | 36 |
| Alendronate Sodium | Alendronate Sodium | 82 | 28 |
| Alprazolam | Alprazolam | 81 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 79 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 50 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 71 | 34 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 68 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 17 |
| Allopurinol | Allopurinol | 64 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 19 |
| Ibuprofen | Ibuprofen | 63 | 36 |
| Jardiance | Empagliflozin | 63 | 20 |
| Januvia | Sitagliptin Phosphate | 62 | 19 |
| Mounjaro | Tirzepatide | 61 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 57 | 22 |
| Hydrocortisone | Hydrocortisone | 56 | 36 |
| Clonidine Hcl | Clonidine Hcl | 54 | 20 |
| Farxiga | Dapagliflozin Propanediol | 53 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 53 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 33 |
| Fenofibrate | Fenofibrate | 52 | 16 |
| Montelukast Sodium | Montelukast Sodium | 51 | 20 |
| Famotidine | Famotidine | 48 | 22 |
| Tivicay | Dolutegravir Sodium | 48 | 11 |
| Enalapril Maleate | Enalapril Maleate | 47 | 15 |
| Entresto | Sacubitril/Valsartan | 43 | 12 |
| Valsartan | Valsartan | 43 | 13 |
| Celecoxib | Celecoxib | 42 | 19 |
| Delstrigo | Doravirine/Lamivu/Tenofov Diso | 41 | suppressed |
| Omeprazole | Omeprazole | 41 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 18 |
| Prezcobix | Darunavir/Cobicistat | 41 | suppressed |
| Levofloxacin | Levofloxacin | 40 | 34 |
| Ammonium Lactate | Ammonium Lactate | 39 | 26 |
| Meclizine Hcl | Meclizine Hcl | 39 | 25 |
| Lactulose | Lactulose | 38 | 20 |
| Nifedipine Er | Nifedipine | 37 | 16 |
| Ozempic | Semaglutide | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 14 |
| Mupirocin | Mupirocin | 36 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | 13 |
| Repaglinide | Repaglinide | 33 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 21 |
| Clonidine | Clonidine | 30 | 12 |
| Levetiracetam | Levetiracetam | 30 | 12 |
| Nystatin | Nystatin | 30 | 20 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | 11 |
| Amoxicillin | Amoxicillin | 26 | 23 |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | 11 |
| Donepezil Hcl | Donepezil Hcl | 25 | 11 |
| Juluca | Dolutegravir/Rilpivirine | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 24 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 17 |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | 12 |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 13 |
| Torsemide | Torsemide | 20 | suppressed |
| Daptomycin | Daptomycin | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 15 | 12 |
| Tradjenta | Linagliptin | 15 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Rukobia | Fostemsavir Tromethamine | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | 13 |
| Trulicity | Dulaglutide | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,192.65 · 58 records | AstraZeneca Pharmaceuticals LP | Arikayce, BREZTRI, Biktarvy, Brinsupri, CABENUVA, CAPVAXIVE, EGRIFTA, FARXIGA, FASENRA, GVOKE HYPOPEN, Ozempic, PIFELTRO, PURIFIED CORTROPHIN GEL, REPATHA, TREMFYA, TROGARZO, VOWST, Veklury, Wegovy | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error